Clinical Applications

At BabyCord we have the unique ability to store both cord blood and umbilical cord tissue. Banking cord blood and tissue is an irreplaceable opportunity to preserve potentially life-saving cells that are commonly discarded after birth. Umbilical cord blood banking is a safe and completely non-invasive intervention allowing patients future access to the therapeutic value of stem cells. These optimally stored cells have the ability to divide for indefinite periods in culture producing specialized tissue cells.

With over 30,000 reported treatments of acute and chronic diseases, cord blood banking is currently among the best ways to harvest the hematopoietic stem cells that can self-divide and separated into red blood cells, white blood cells and platelets. 

Cells in the umbilical cord blood and bone marrow are known as hematopoietic progenitor cells with an estimated 50,000 hematopoietic cell transplantations performed each year to treat malignant diseases. Furthermore, stem cells found in cord blood and cord tissue have the ability to transform into most human cell lines with future capabilities to treat conditions like diabetes, heart disease, cancer, spinal cord injury, genetic diseases, and many more.

Stem cells in cord blood and cord tissue consist primarily of hematopoietic and mesenchymal stem cells, respectively. Hematopoietic stem cells give rise to all blood cell types including myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells), and lymphoid lineages (T-cells, B-cells, NK-cells). They are most commonly used to treat cancers, blood disorders, immunodeficiencies and metabolic diseases. Stem cells from cord blood are easily collected and stored with high engraftment rates and reduced risk of graft versus host disease.

Mesenchymal stem cells (MSCs) are multipotent that can self-divide into a variety of cell types including osteoblasts, chondrocytes, myocytes, adipocytes, and recently, beta-pancreatic islets cells. They are mainly used to treat chronic disease, enhance the regeneration of nervous system and restore damaged tissue and organs. Fetal or cord-type MSCs demonstrate higher proliferation potential and lower level HLA-class I suggesting lower immunogenicity when compared to adult-type MSCs like those found in bone marrow. Furthermore, extracting bone marrow MSCs is an invasively painful procedure that may cause infection, bleeding, and chronic pain in addition to exhibiting accelerated senescence. A growing body of research data suggests wide therapeutic potential for MSCs, with the ability of high engraftment rates and low risk of graft versus host disease.

Transplants by Cell Source

©  BabyCord, All rights reserved.ESKADENIA Software Logo